MRNANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Moderna, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 31, 2026

$226.89+8.88 (+4.07%)

Close on Oct 19, 2026

Market cap: $90.30B
P/E (TTM): –
Dividend yield: –

Dividends

Moderna has not reported a dividend

No dividend per share appears in Moderna's annual filings since fiscal 2015.

Where these numbers come from

Parsed from the XBRL in Moderna's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is MRNA.

Revenue growth-27.6% · median 4.8%

Gross margin23.4% · median 87.5%

Operating margin-149.0% · median -33.3%

Net margin-141.4% · median -16.3%

Company	Revenue	Growth
BIIB	$10.03B	+0.3%
EXEL	$2.44B	+9.2%
MRNA	$2.23B	-27.6%
BCRX	$940.61M	+68.7%
NVAX	$413.80M	-61.6%
BNTX	–	–

Company

Next earnings (est.): Nov 5, 2026, before open
Exchange: Nasdaq
Industry: Biological Products, (No Diagnostic Substances)
Fiscal year ends: December 31
Employees: 4,700
Held by institutions: 79.9%
Auditor: Ernst & Young LLP
SEC CIK: 1682852

Advertisement
300 × 250